The Asia Pacific Genomics In Cancer Care Market would witness market growth of 16.3% CAGR during the forecast period (2024-2031).
The China market dominated the Asia Pacific Genomics In Cancer Care Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $4.04 billion by 2031. The Japan market is registering a CAGR of 15.7% during (2024 - 2031). Additionally, The India market would showcase a CAGR of 17% during (2024 - 2031).
Genomic analysis of cancer cells can identify tumor-specific antigens - unique proteins produced by cancer cells do not present in normal cells. These antigens can be targeted for immunotherapy, enabling the development of personalized cancer vaccines and other immune-based therapies designed to enhance the immune system’s ability to recognize and attack cancer cells.
Moreover, genomic profiling of tumors can inform the customization of radiation therapy. By understanding cancer cells’ specific genetic alterations and repair mechanisms, clinicians can tailor radiation doses and treatment schedules to maximize effectiveness while minimizing damage to surrounding healthy tissues. This approach, known as precision radiotherapy, improves treatment outcomes and reduces side effects.
The expansion of the hospital sector in India has resulted in developing new and upgraded healthcare facilities, including those specializing in cancer care. These hospitals are increasingly equipped with state-of-the-art genomic technologies for diagnostics and treatment, thereby driving demand for genomics in cancer care. As per the data published by the National Investment Promotion and Facilitation Agency of India, the hospital industry in India, which accounts for 80% of the entire healthcare industry, is experiencing high investment demand from international and domestic investors. The healthcare industry was expected to rise to $132 billion by 2023.
Based on Application, the market is segmented into Diagnostics, Personalized Medicine, Drug Discovery & Development, and Research. Based on Product, the market is segmented into Instruments, Consumables, Services. Based on Technology, the market is segmented into PCR, Genome Sequencing, Microarrays, Nuclei Acid Extraction & Purification, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The China market dominated the Asia Pacific Genomics In Cancer Care Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $4.04 billion by 2031. The Japan market is registering a CAGR of 15.7% during (2024 - 2031). Additionally, The India market would showcase a CAGR of 17% during (2024 - 2031).
Genomic analysis of cancer cells can identify tumor-specific antigens - unique proteins produced by cancer cells do not present in normal cells. These antigens can be targeted for immunotherapy, enabling the development of personalized cancer vaccines and other immune-based therapies designed to enhance the immune system’s ability to recognize and attack cancer cells.
Moreover, genomic profiling of tumors can inform the customization of radiation therapy. By understanding cancer cells’ specific genetic alterations and repair mechanisms, clinicians can tailor radiation doses and treatment schedules to maximize effectiveness while minimizing damage to surrounding healthy tissues. This approach, known as precision radiotherapy, improves treatment outcomes and reduces side effects.
The expansion of the hospital sector in India has resulted in developing new and upgraded healthcare facilities, including those specializing in cancer care. These hospitals are increasingly equipped with state-of-the-art genomic technologies for diagnostics and treatment, thereby driving demand for genomics in cancer care. As per the data published by the National Investment Promotion and Facilitation Agency of India, the hospital industry in India, which accounts for 80% of the entire healthcare industry, is experiencing high investment demand from international and domestic investors. The healthcare industry was expected to rise to $132 billion by 2023.
Based on Application, the market is segmented into Diagnostics, Personalized Medicine, Drug Discovery & Development, and Research. Based on Product, the market is segmented into Instruments, Consumables, Services. Based on Technology, the market is segmented into PCR, Genome Sequencing, Microarrays, Nuclei Acid Extraction & Purification, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
List of Key Companies Profiled
- Agilent Technologies, Inc.
- F.Hoffmann-La Roche Ltd.
- Danaher Corporation (Beckman Coulter, Inc.)
- Abbott Laboratories
- Bio-Rad Laboratories, Inc.
- GE HealthCare Technologies, Inc.
- Quest Diagnostics Incorporated
- Revvity, Inc.
- Eurofins Scientific SE
- Hologic, Inc.
Market Report Segmentation
By Application- Diagnostics
- Personalized Medicine
- Drug Discovery & Development
- Research
- Instruments
- Consumables
- Services
- PCR
- Genome Sequencing
- Microarrays
- Nuclei Acid Extraction & Purification
- Others
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Competition Analysis - Global
Chapter 5. Asia Pacific Genomics In Cancer Care Market by Application
Chapter 6. Asia Pacific Genomics In Cancer Care Market by Product
Chapter 7. Asia Pacific Genomics In Cancer Care Market by Technology
Chapter 8. Asia Pacific Genomics In Cancer Care Market by Country
Chapter 9. Company Profiles
Companies Mentioned
- Agilent Technologies, Inc.
- F. Hoffmann-La Roche Ltd.
- Danaher Corporation (Beckman Coulter, Inc.)
- Abbott Laboratories
- Bio-Rad Laboratories, Inc.
- GE HealthCare Technologies, Inc.
- Quest Diagnostics Incorporated
- Revvity, Inc.
- Eurofins Scientific SE
- Hologic, Inc.
Methodology
LOADING...
